Is there an effective treatment for late-onset systemic lupus erythematosus?

Ugarte Gil, Manuel Francisco; Alarcón, Graciela S.

dc.contributor.author	Ugarte Gil, Manuel Francisco
dc.contributor.author	Alarcón, Graciela S.
dc.date.accessioned	2022-01-04T20:29:52Z
dc.date.available	2022-01-04T20:29:52Z
dc.date.issued	2013
dc.identifier.uri	https://hdl.handle.net/20.500.12866/10348
dc.description.abstract	Over the past 60 years, overall mortality in systemic lupus erythematosus patients has dramatically decreased, but late mortality, which relates to the damage caused by the disease, its treatments and/or evolving comorbidities, is still high. This is particularly true in patients with late-onset lupus, a special subgroup of patients who, despite not having very active disease, experience a larger number of comorbidities, and higher damage accrual and mortality rates than early-onset patients. Treating these late-onset patients can be more difficult due to the risk of drug–drug interactions and aging-related processes. Antimalarials should be used whenever possible, and glucocorticoids and immunosuppressive drugs must used be carefully, especially in this population. NSAIDs should be avoided if possible. Adequate treatment of comorbidities should improve these patients’ prognoses.	en_US
dc.language.iso	eng
dc.publisher	Future Science Group
dc.relation.ispartofseries	Aging Health
dc.rights	info:eu-repo/semantics/restrictedAccess
dc.subject	Epidemiology	en_US
dc.subject	epidemiology of systemic lupus erythematosus	en_US
dc.subject	late-onset	en_US
dc.subject	systemic lupus erythematosus	en_US
dc.subject	treatment	en_US
dc.title	Is there an effective treatment for late-onset systemic lupus erythematosus?	en_US
dc.type	info:eu-repo/semantics/article
dc.identifier.doi	https://doi.org/10.2217/ahe.13.36
dc.subject.ocde	https://purl.org/pe-repo/ocde/ford#3.02.26
dc.relation.issn	1745-5103